ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impaired social interaction · children aged 5 to 11 years with ASD
1 finding from 1 review
Social communication impairment · children aged 5 to 11 years with ASD
1 finding from 1 review
Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐core symptoms of ASD · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in non‐core symptoms of ASD compared with placebo (low certainty).
1 finding from 1 review
Tolerability · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in tolerability compared with placebo (low certainty).
1 finding from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–6 years)
The review found no eligible studies for this question.
2 findings from 1 review
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–6 years)
2 findings from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–4 years)
1 finding from 1 review
Household dust: floor dust lead levels · children (aged 0–4 years)
1 finding from 1 review
Adverse events · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–2 years)
1 finding from 1 review
Floor dust ‐ hard floor (continuous) Floor dust lead levels Scale from: 0 to 40 · children (aged 0–2 years)
1 finding from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–6 years)
2 findings from 1 review
Household dust: floor dust lead levels · children (aged 0–6 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found